Sun, Sep 21, 2025
1- JIPMER, Puducherry
2- JIPMER, Puducherry ,shuruthi99k@gmail.com
3- All India Institute of Medical Sciences, Patna
2- JIPMER, Puducherry ,
3- All India Institute of Medical Sciences, Patna
Abstract: (37 Views)
ABSTRACT
Background: The emergence of multi-drug resistant organisms has limited the choice of therapeutic options to treat infections. The lack of development of new antimicrobials paved the way for considering the reassessment of older antibiotics like fosfomycin. In this context, we assessed the in-vitro effect of fosfomycin against carbapenem- resistant Enterobacterales and methicillin-resistant Staphylococcus aureus on bloodstream isolates by agar dilution, disk diffusion and screen agar.
Material & Methods: All the 141 consecutive blood isolates which were resistant to carbapenem and 62 MRSA blood culture isolates were collected over a period of 8 months. The methods such as fosfomycin agar dilution (0.25 µg/ml to 512 µg/ml) , Kirby-Bauer disk diffusion (150μg of fosfomycin + 50μg of glucose -6-phosphate) and fosfomycin screen agar (32 µg/ml, 48µg/ml & 64µg/ml) were performed. All the three methods are interpreted using EUCAST guidelines. The agreement between the new method and the reference method was calculated.
Results: Among the tested isolates, 100 % of MRSA followed by E. coli (86.4%), K.pneumoniae (65.2%) and E.cloacae (50%) were susceptible to fosfomycin. The MIC50 and MIC90 of fosfomycin was 0.5µg/ml and 2µg/ml for MRSA, 16µg/ml and 32µg/ml for K.pneumoniae, 4µg/ml and 16µg/ml for E.coli, 8µg/ml and 32µg/ml for E.cloacae respectively.
Conclusion: In this study, we observed that fosfomycin has a good in-vitro effect on most of the carbapenem resistant Enterobacterales and MRSA isolates tested.
Key words: Fosfomycin; susceptibility testing; antibiotic resistance; MRSA; carbapenem resistant Enterobacterales; MIC
Short running title: In vitro fosfomycin susceptibility
Background: The emergence of multi-drug resistant organisms has limited the choice of therapeutic options to treat infections. The lack of development of new antimicrobials paved the way for considering the reassessment of older antibiotics like fosfomycin. In this context, we assessed the in-vitro effect of fosfomycin against carbapenem- resistant Enterobacterales and methicillin-resistant Staphylococcus aureus on bloodstream isolates by agar dilution, disk diffusion and screen agar.
Material & Methods: All the 141 consecutive blood isolates which were resistant to carbapenem and 62 MRSA blood culture isolates were collected over a period of 8 months. The methods such as fosfomycin agar dilution (0.25 µg/ml to 512 µg/ml) , Kirby-Bauer disk diffusion (150μg of fosfomycin + 50μg of glucose -6-phosphate) and fosfomycin screen agar (32 µg/ml, 48µg/ml & 64µg/ml) were performed. All the three methods are interpreted using EUCAST guidelines. The agreement between the new method and the reference method was calculated.
Results: Among the tested isolates, 100 % of MRSA followed by E. coli (86.4%), K.pneumoniae (65.2%) and E.cloacae (50%) were susceptible to fosfomycin. The MIC50 and MIC90 of fosfomycin was 0.5µg/ml and 2µg/ml for MRSA, 16µg/ml and 32µg/ml for K.pneumoniae, 4µg/ml and 16µg/ml for E.coli, 8µg/ml and 32µg/ml for E.cloacae respectively.
Conclusion: In this study, we observed that fosfomycin has a good in-vitro effect on most of the carbapenem resistant Enterobacterales and MRSA isolates tested.
Key words: Fosfomycin; susceptibility testing; antibiotic resistance; MRSA; carbapenem resistant Enterobacterales; MIC
Short running title: In vitro fosfomycin susceptibility
Keywords: Fosfomycin, susceptibility testing, antibiotic resistance, MRSA, carbapenem resistant Enterobacterales, MIC
Research Article: Research Article |
Subject:
Microbiology
Received: 2023/03/6 | Accepted: 2023/06/17
Received: 2023/03/6 | Accepted: 2023/06/17
References
1. Christaki E, Marcou M, Tofarides A. Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence. J Mol Evol. 2020;88(1):26-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Morrison L, Zembower TR. Antimicrobial Resistance. Gastrointest Endosc Clin N Am. 2020;30(4):619-35. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Septimus EJ. Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach. Med Clin North Am. 2018;102(5):819-29. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Kaase M, Szabados F, Anders A, Gatermann SG. Fosfomycin susceptibility in carbapenem-resistant Enterobacterales from Germany. J Clin Microbiol. 2014;52(6):1893-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacterales: an evolving crisis of global dimensions.Clin Microbiol Rev. 2012;25(4):682-707. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Patil SS, Suresh KP, Shinduja R, Amachawadi RG, Chandrashekar S, Pradeep S, et al. Prevalence of methicillin-resistant Staphylococcus aureus in India: a systematic review and meta-analysis. Oman Med J. 2022;37(4):e440. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. World Health Organization. Critically important antimicrobials for human medicine,6th Revision. [View at Publisher] [Google Scholar]
8. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-47. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Aprile A, Scalia G, Stefani S, Mezzatesta ML. In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacterales. J Glob Antimicrob Resist. 2020;23:286-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpreters. Version 11.0, 2021. http://www.eucast.org [View at Publisher]
11. CLSI M100, 2022 Edition, February 2022 - Performance Standards for Antimicrobial Susceptibility Testing. [View at Publisher]
12. CLSI M02 Performance Standards for Antimicrobial Disk Susceptibility Tests, 13th Edition. [View at Publisher]
13. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies.Expert Opin Investig Drugs. 2009;18(7):921-44. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. De Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother. 2006;50(1):368-70. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Li R, Tang H, Xu H, Ren Y, Li S, Shen J. Direct-on-target microdroplet growth assay applications for clinical antimicrobial susceptibility testing. Infect Drug Resist. 2021;14:1423-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(3):240-3. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.Int J Antimicrob Agents. 2011;37(5):415-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Williams PC, Waichungo J, Gordon NC, Sharland M, Murunga S, Kamau A, et al. The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria. J Med Microbiol. 2019;68(5):711-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, et al. In vitro activity of fosfomycin against bla KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54(1):526-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Pasteran F, Lucero C, Rapoport M, Guerriero L, Barreiro I, Albornoz E, et al. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae. J Infect Dev Ctries. 2012;6(5):452-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Behera B, Mohanty S, Sahu S, Praharaj AK. In vitro activity of fosfomycin against multidrug-resistant urinary and nonurinary Gram-negative isolates. Indian J Crit Care Med. 2018;22(7):533-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Gopichand P, Agarwal G, Natarajan M, Mandal J, Deepanjali S, Parameswaran S, et al. In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections. Infect Drug Resist. 2019;12:2005-13. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Mittal S, Sharma M, Chaudhary U. Fosfomycin use in multi drug resistant uropathogenic Escherichia coli. Infect Disord Drug Targets.
2015;15(3):196-201. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Rajenderan S, Balaji V, Anandan S, Sahni RD, Tansarli GS, Falagas ME. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study. PLoS One. 2014;9(7):e103253. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Sahni RD, Balaji V, Varghese R, John J, Tansarli GS, Falagas ME. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study. Future Microbiol. 2013;8(5):675-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Campanile F, Wootton M, Davies L, Aprile A, Mirabile A, Pomponio S, et al. Gold standard susceptibility testing of fosfomycin in Staphylococcus aureus and Enterobacterales using a new agar dilution panel®. J Glob Antimicrob Resist. 2020;23:334-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.